Dr. Gaytri Kachroo

CEO and Chairman


Dr. Gaytri Kachroo, originally from India, now calls both Canada and the U.S. her home. She has 25 years of experience as a litigator and corporate lawyer, admitted to practice in Quebec, Massachusetts and New York. She has obtained five law degrees including an LLM and SJD from the Harvard Law School. She has co-chaired international practice groups and India practices at two law firms in the Boston area and has headed the corporate department of one such law firm. She practices transactional domestic and international business law, and has represented small and medium sized enterprises (SMEs) and multi-national corporations (MNCs) in mergers and acquisitions, outsourcing, technology licensing, joint ventures and cross-border issues. Her corporate clients include life science, technology, outsourcing, energy and financial sector companies.


Her vast experience and education prompted Harry Markopolos to hire her in 2005 to build a business model for his fraud investigation business when no other law firms could or would.


When the Madoff fraud finally blew in December 2008, she became the fifth Fox Hound and coined the groupís name "Fox Hounds." She represented Harry Markopolos before Congress (extensively preparing him for and assisting with his written and oral testimony), and later representing his whistleblower team before the SEC Inspector General. Her in depth review of the Madoff investigation now informs her advisory and litigation practice relating to financial fraud. Further, her appointment as Vice-Chair of the Global Alliance on the Madoff case (a civil society of some 5000 lawyers from 28 countries) and leadership have lead to discussions between the EU-US on a new adjudicative mechanism for transnational financial fraud. Additionally, she has presented a proposal for a new International Financial Tribunal to the World Legal Forum at the Hague in December, 2009 to handle cross-border financial fraud disputes. She has founded the International Center for Corporate and Financial Ethics and Responsibility in Cambridge, MA., as well as her own law firm, Kachroo Legal Services, P.C.


Additionally, Dr. Kachroo has chaired the Board of World Boston and the international law section of the Boston Bar. She now continues her work on both of those boards among other community and professional service organizations.

Gary W. Jay, MD, FAAPM

Chief Medical Officer/Head Regulatory Affairs


Dr. Jay spent his first 25 years as owner and Medical Director of the first private interdisciplinary pain center west of the Mississippi, where he treated more than 30,000 patients presenting with every type of headache, pain and CNS abnormality. He has worked extensively as a PI, Key Opinion Leader, and Consultant to the Pharma industry on both clinical trial development and regulatory affairs. He was one of the founders of the American Academy of Pain Medicine in 1983, the American Academy of Pain Management in 1988 and is currently the President of the Eastern Pain Association. He has published 5 textbooks, and more than 110 peer reviewed journal articles. He joined Pharma full time in 2005 as a Medical Director at Schwarz - acquired by UCB; then 3 years at Pfizer as the Clinical Disease Area Expert- Pain; and then as Chief Medical Officer at Archimedes.

Michael R. Ruff, PhD

Chief Scientific Officer

Dr. Ruff is an immunologist and virologist specialized in infectious diseases. Dr. Ruff is the co-inventor of Peptide T with Dr. Candace Pert and the author of some 80 peer reviewed scientific articles on immune cells and receptors. He is also the inventor of many patents. Dr. Ruff received advanced training in immunology and virology at the National Institutes of Health and the University of Zurich. Dr. Ruff was most recently a research professor at Georgetown University Medical School. He has over 20 years experience in the creation of receptor active small peptide drugs.

Maria Polianova, PhD
Laboratory Director

Dr. Polianova received her PhD from the National Institute of Infectious and Parasitic Diseases, Sofia, Bulgaria. As associate professor in the AIDS Reference Laboratory, Dr. Polianova introduced the molecular diagnostics of HIV into Bulgaria, after specialized HIV training at Hoffman LaRoche and the Japanese NIH. She has published over thirty papers in retrovirology. While holding positions at the NCI, NIH, and Georgetown University, she proved the mechanism of action of DAPTA as a CCR5 entry inhibitor of HIV-1 infection and published on clinical improvements. Dr. Polianova has six years experience as a scientist at Wellstat, a small biotechnology R&D, where she developed and qualified five cell-based assays in compliance with FDA regulations.

To top

Kirin Kachroo-Levine
Manager, Financial Analysis

Mr. Kachroo-Levine graduated from Reed College with a degree in Economics. After writing his undergraduate thesis on pricing in renewable energy certificate markets, he consulted for a renewable energy startup and served as Controller of a law firm, where he managed liquidity, sales, payroll, and all accounting functions. He is currently working towards his CFA.